References
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org. Accessed September 6, 2012.
- CelliBRMacNeeWATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEur Respir J20042393294615219010
- NiewohnerDEClinical practice. Outpatients management of severe COPDN Engl J Med20103621407141620393177
- UlrikCSEfficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, cross-over studyThorax1995507507547570409
- BeehKMWagnerFKhindriSDrollmannAFThe effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPDCOPD2011834034521793716
- BarnesPJThe role of anticholinergics in chronic obstructive pulmonary diseaseAm J Med200411724S32S15693640
- HodderRTiotropium is superior to salmeterol in reducing frequency of exacerbations: but the effect of adding tiotropium to the combination of inhaled corticosteroid and long-acting β2-agonist remains unclearEvid Based Med201217939522108077
- SykesDADowlingMRCharltonSJExploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptorMol Pharmacol20097654355119498041
- VogelmeierCBanerjiDNVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary diseaseTher Adv Respir Dis2011516317321511677
- SechaudRRanardDZhang-AubersonLde la MotteSDrollmannAKaiserGPharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD)Int J Clin Pharmacol Ther20125011812822257577
- VestboJVogelmeierCCreemersJFaiquesMRiberaAGilEGOnset of effect of aclidinium, a novel long-acting muscarinic antagonist, in patients with COPDCOPD2010733133620854047
- Van de MaeleBFabbriLMMartinCHortonRDolkerMOverendTCardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patientsCOPD2010741842721166630
- SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysisJAMA20083001439145018812535
- VerkindreCFukuchiYFlemaleASustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsRespir Med20101041482148920541381
- VogelmeierCVerkindreCCheungDSafety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsPulm Pharmacol Ther20102343844420416390
- FogartyCHattersleyHDi ScalaLDrollmannABronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patientsRespir Med201110533734221144724
- CasaburiRConoscentiCSLung function improvements with once-daily tiotropium in chronic obstructive pulmonary diseaseAm J Med200411733S40S15693641
- D’UrzuAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate to severe COPD: the GLOW1 trialRespir Res20111215622151296
- KerwinEHebertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium inpatients with moderate-to-severe COPD over 52 weeks: The GLOW2 studyEur Respir J2012
- O’DonnellDECasaburiRVinckenNEffect of indacaterol on exercise endurance time and lung hyperinflation in COPDRespir Med20111051030103621498063
- O’DonnellDEFlugeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPDEur Respir J20042383284015218994
- MaltaisFCelliBCasaburiRAclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPDRespir Med201110558058721183326
- BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J COPD20127503513
- CasaburiRFactors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventionsCOPD2005213113617136973
- JonesiPWRennardSIAgustiAEfficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseRespir Res2011125521518460